Seroprevalence study results to SARS-CoV-2 in healthcare workers: age and professional aspects

Relevance. Age-related and occupational aspects of SARS-CoV-2 seroprevalence in healthcare workers are not well understood. Aims: Conduct a selective study of seroprevalence to the SARS-CoV-2 virus among 348 medical workers of 10 medical organizations in Kazan: seven multidisciplinary hospitals that have been re-profiled to provide medical care to patients with coronavirus infection, an ambulance station, a medical organization that carries out outpatient activities and a specialized clinic. Materials and methods. Among those surveyed on a professional basis, the groups «Doctors», «Nurses», «Junior medical personnel», «Other medical workers» were identified. The age structure of seroprevalence was studied in groups of 18–29, 30–39, 40–49, 50–59 and 60–69 years. For the determination of IgG, a solid-phase ELISA was used. Results. The proportion of medical workers (MR) of various medical organizations in Kazan seropositive for IgG to the SARS-CoV-2 virus is 16.4%. The wide variation in the seroprevalence value of MR groups of different medical organizations (3.3–30.8%) may indicate a different level of effectiveness of anti-epidemic measures in these institutions. The maximum rate was noted in the age groups – 18–29 years (21%) and 60-69 years (18.2%). According to the professional criterion, a comparable level of seroprevalence is shown for the categories «Doctors» and «Nurses» with a wide variation in indicators in professional groups, depending on a particular medical organization. The obtained results indicate the presence among medical workers who have suffered or have an asymptomatic course of infection caused by SARS-CoV-2, and confirm the relevance of further serological monitoring in medical organizations of various profiles. The results of serological monitoring, taking into account age and professional aspects, can serve as the basis for adjusting preventive measures on the basis of individual medical organizations, and taking into account the recommendations of Rospotrebnadzor and the selection of contingents for vaccination against SARS-CoV-2. Conclusions: For the MR of various medical institutions in Kazan, the seroprevalence for antibodies to the SARS-CoV-2 virus is 16.4%; Age aspects affect the level of seroprevalence in MR; The obtained results indicate the presence of persons among MR who have had or have an asymptomatic course of infection caused by SARS-CoV-2, and confirm the relevance of further serological monitoring in medical organizations of various profiles.

1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med.2020;382(8):727–733. doi: 10.1056/NEJMoa2001017.

2. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARSCoV-2. Nat Microbiol. 2020;5(4):536–544. doi: 10.1038/s41564-020-0695-z.

3. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA. 2020 May 6. DOI: 10.1001/jama.2020.8259.

4. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020 Apr 29. DOI: 10.1038/s41591-020-0897-1.

5. Wu F, Wang A, Liu M, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. Preprint at medRxiv. Available at: https://doi.org/10.1101/2020.03.30.20047365.

6. Kellam P, BarclayW. The dynamics of humoral immune responses following SARS- CoV-2 infection and the potential for reinfection. Journal of General Virology DOI/10/11099/jgv.0.001439.

7. COVID-19-EPIDEMIC : Immunity after SARS-CoV-2 infection– a rapid review. Available at: https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2020/immunity-after-sars-cov-2infection-1stupdate-report-2020.

8. Tao Liu, Sanyun Wu, Huangheng Tao et al. Prevalence of IgG antibodies to SARS-CoV-2 in Wuhan - implications for theability to 13 produce long-lasting protective antibodies against SARS-CoV-2 doi: https://doi.org/10.1101/2020.06.13.20130252.

9. Hains DS, Schwaderer AL, Carroll AE, et al. Asymptomatic Seroconversion of Immunoglobulins to SARS-CoV-2 ina Pediatric Dialysis Unit. JAMA. 2020 May 14: e208438. DOI:10.1001/jama.2020.8438.

10. Popova A. YU., Ezhlova E. B., Mel’nikova A. A. et al. Populyacionnyj immunitet k virusu SARS-CoV-2 sredi naseleniya Sankt-Peterburga v aktivnuyu fazu epidemiii COVID-19. COVID19-PREPRINTS.MICROBE.RU. 2020. (in Rus). https://doi.org/10.21055/preprints-3111752.

11. Kutyrev V.V., Popova A.YU., Smolenskij V.YU., et al. Epidemiologicheskie osobennosti novoj koronavirusnoj infekcii (COVID-19). Soobshchenie 2: osobennosti techeniya epidemicheskogo processa COVID-19vo vzaimosvyazi s provodimymi protivoepidemicheskimimeropriyatiyami v mire i Rossijskoj Federacii. Problemy osobo opasnyh infekcij. 2020;(2):6–12. https://doi.org/10.21055/0370-1069-2020-2-6-12)

12. Udovichenko S. K. Epidemicheskie proyavleniya COVID-19 na territorii Volgogradskoj oblasti. COVID19-PREPRINTS.MICROBE.RU. 2020. https://doi.org/10.21055/preprints-3111740

13. Stepanova T. F., Sharuho G. V., Letyushev A. N., et al. Primenenie metodov analiza i prognozirovaniya vremennyh ryadov epidemiologicheskoj situacii novoj koronavirusnoj infekcii (COVID-19) v Tyumenskoj oblasti. COVID19-PREPRINTS.MICROBE.RU. 2020. https://doi.org/10.21055/preprints-3111766.

14. Protokol populyacionnogo stratificirovannogo po vozrastu seroepidemiologicheskogo issledovaniya infekcii COVID-19 u cheloveka Versiya: 2.0 Data: 26 maya 2020 g. WHO/2019-nCoV/Seroepidemiology/2020.2. (in Rus).

15. Smirnov V.S., Zarubaev V.V., Petlenko S.V. Biologiya vozbuditelej i kontrol’ grippa i ORVI. SPb: Gippokrat, 2020. SPb: Gippokrat, (in Rus).

16. Al-Tawfiq JA. Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19). Travel Med Infect Dis. 2020;35:101608. doi:10.1016/j.tmaid.2020.101608.

17. Gao Z, Xu Y, Sun C, et al. A Systematic Review of Asymptomatic Infections with COVID-J Microbiol Immunol Infect. 2020;10.1016/j.jmii.2020.05.001. doi:10.1016/j.jmii.2020.05.001.

18. Semenov A.V., Pshenichnaya N.YU. Uroki epidemii COVID-19 v Italii. Infekciya i immunitet. 2020;10(3):410–420. https://doi.org/10.15789/2220-7619-LTL-1468.